The paywalled retraction notice simply cites a “nonscientific reason.” Cody Mooneyhan, the director of publications at the journal, declined to provide further details, and the authors have provided different accounts of what happened: The paper’s corresponding author, John Yu, told Retraction Watch that he requested the retraction because the first author, Chia‐Ti Tsai, refused to sign the journal’s copyright agreement. Tsai, a professor in the Department of Internal Medicine at National Taiwan University in Taipei, told us he was “not notified before the paper was submitted.” Continue reading Authors retract heart disease paper for “nonscientific reason”
For a host of reasons, a journal has retracted a paper co-authored by a researcher who reportedly once faced charges of practicing medicine without proper qualifications.
According to the retraction notice for “Psorinum Therapy in Treating Stomach, Gall Bladder, Pancreatic, and Liver Cancers: A Prospective Clinical Study,” published Dec. 8, 2010 in Evidence-Based Complementary and Alternative Medicine, the paper was plagued by:
A pharmacy journal has retracted a 2017 cancer paper after determining that the lead author forged her co-author’s signature.
Alain Li Wan Po, editor-in-chief of the Journal of Clinical Pharmacy and Therapeutics, told Retraction Watch that, after discovering the forgery, the journal lost confidence in “the integrity of the whole report,” and decided to retract it:
Our judgment was that if an author is willing to forge a signature, we cannot be sure of the integrity of the whole report and decided on the retraction.
According to Po, the paper’s lead author, Yan Wang, objected to the retraction because “she maintained that the data were accurate.” So the editors retracted the paper without her approval — but with the agreement of the author Jatinder Lamba, whose name was forged.
How did the journal discover the forged signature?
A journal has retracted a 2014 paper because of an authorship dispute that became the subject of litigation.
Last year, the Allegheny Health Network in Pittsburgh requested the paper be retracted to resolve the dispute. The Journal of Applied Biomaterials & Functional Materials retracted the paper in October.
According to the retraction notice, the principal investigator of a clinical trial on which some of the study is based was not included as a co-author, and claimed he had not “validated the accuracy of the data.”
The notice does not mention a lawsuit, but a letter from the authors’ research institution does.
Carlo Croce, a cancer researcher who has faced numerous research misconduct allegations, recently accused a former lab member of misconduct. Although an institutional probe did not support that allegation, Croce’s efforts have led to a retraction.
In November 2015, Croce and another cancer researcher at Ohio State University (OSU), Ramiro Garzon, contacted PLOS ONE, alleging that the paper’s corresponding author, Stefan Costinean, published data without their knowledge or permission and without “accurately acknowledging their contributions to the research.” Although the PLOS ONE paper mentioned Croce’s and Garzon’s contributions in the acknowledgements section, the two were not included as co-authors. We have obtained a copy of the report describing OSU’s preliminary probe; it did not find evidence of misconduct, but recommended the paper be retracted for using data without permission. Although Costinean disagreed, the journal has since retracted the paper.
Croce has been on the other side of this process: Seven of his papers have been retracted for issues including manipulation and duplication. After a New York Times article, published in March, explored misconduct allegations against Croce, OSU said the university is “instituting an independent external review.” Croce is currently suing the New York Times, alleging that the newspaper defamed him in the story.
In 1980, Leila Tov-Ruach published a book chapter in which she thanked the editor of the book, Amélie Oksenberg Rorty, “for the hospitality that made the writing of this paper possible.”
Normally, such an acknowledgement wouldn’t raise eyebrows. But, the trouble is, Tov-Ruach and Rorty are the same person: Leila Tov-Ruach is a pseudonym for Rorty, an accomplished philosopher. The University of California Press (UC Press) officially outed Rorty as Leila Tov-Ruach when it issued corrections for two chapters she published decades ago under the pseudonym (1, 2).
The corrections explain the author of the chapters is Rorty, who also edited the two books in which the chapters appear. Although Rorty didn’t note in the original versions of the books that she is Tov-Ruach, she has not tried to hide her pseudonym either. She has acknowledged she is Tov-Ruach in her CV, and at least some philosophers know about the pseudonym (1, 2).
Why would a philosopher—who has an impressive publishing record that spans 50 years and, at 85 years old, is still a lecturer at Harvard—choose to write under a fake name?
The paper concerned research on Fragile X syndrome (FXS), characterized by both intellectual and physical abnormalities, which is linked autism. A compound that passed through phase 2 clinical trials in October 2015 appeared to partially treat FXS in mice in the study, published earlier this year.
The journal’s notice says the paper was retracted over a dispute among authors about the order in which they are listed on the paper: Continue reading Dispute over author order torpedoes paper on syndrome linked to autism
In February 2016, Albert Jambon received some puzzling news.
Several colleagues had alerted him to a paper, published online in late December 2015 in the Journal of African Earth Sciences (JAES), reporting the discovery of a rare mineral, which Jambon had been analyzing.
When Jambon read the paper, he realized it was a modified version of a paper he had been working on for almost eight years. Impatient, one of his co-authors, Ahmad Bilal, had published his own version of the manuscript and listed himself as the sole author.
Jambon, a professor at Pierre and Marie Curie University, believes that Bilal’s paper plagiarized his manuscript, but Bilal disputes this allegation. Bilal–who works at Damascus University in Syria–says he couldn’t wait any longer to publish the manuscript, so wrote “a completely new version.” Since the authors couldn’t resolve the authorship dispute, in August 2016, the journal issued a “temporary” expression of concern, alerting readers to the authorship concerns. Now, a year and a half later, a spokesperson for the publisher says it’s going to be retracted.
Eight years is a long time to work on a paper.
Got $300? Then you can be added as an author to a paper — even if you had no role in the research.
That’s right — some journals are willing to add authors to papers they didn’t write, often for a fee. This realization comes from one of the many sting experiments we’ve witnessed over the years, designed to expose the perils of the publishing industry, in which some journals will claim to peer review and publish any manuscript for a fee — no matter how nonsensical the content. Pravin Bolshete, a medical writer and researcher from India, wanted to explore a different side of predatory publishing — would journals agree to add a fictional author to a manuscript he/she didn’t write?
Presenting his findings at the Eighth Peer Review Congress this week in Chicago, Bolshete reported that, after sending hundreds of emails to publishers considered predatory according to the now-defunct (and controversial) list compiled by librarian Jeffrey Beall, 16% agreed to add an author to a paper.
Bolshete told us:
According to the retraction notices, Sato asked the Journal of Neurology, Neurosurgery, and Psychiatry to retract three of his papers “due to scientific misconduct.” In the letter, Sato—who is corresponding author on all three papers—explained he included co-authors without their consent and that none of the other authors listed worked on the study or article.
Here’s the retraction notice for “Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson’s disease:” Continue reading Bone researcher is up to 17 retractions